AICAR

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is a small molecule, not a classic peptide, despite often being grouped with research peptides in catalogs. It is a naturally occurring intermediate in the purine biosynthesis pathway and is best known in research as an activator of AMP-activated protein kinase (AMPK).

Because AMPK acts as a cellular "energy sensor," AICAR has been explored in preclinical settings as a so-called exercise mimetic — a compound hypothesized to reproduce some metabolic signals normally triggered by physical activity. Claims made in commercial and athletic contexts frequently go well beyond what controlled human evidence supports.

AICAR is taken up by cells and phosphorylated to ZMP, a compound that mimics AMP and thereby activates AMPK. Proposed downstream themes, drawn largely from preclinical models, include:

• Activation of AMPK, a central regulator of cellular energy balance
• Signaling associated with mitochondrial biogenesis and oxidative capacity
• Increased glucose uptake in muscle tissue independent of insulin signaling
• Shifts toward fatty-acid oxidation and away from energy storage

How reliably these cellular effects translate into meaningful endurance, metabolic, or body-composition outcomes in humans remains an open research question rather than an established fact.

AICAR is not an approved medicine for performance enhancement, weight management, or metabolic disease in general clinical use. It has appeared primarily as a laboratory reagent and as an investigational agent in research on metabolism and ischemia-related contexts.

Much of the public interest stems from animal studies suggesting endurance-related effects. Extrapolating those findings to healthy humans is not supported by robust clinical trials, and any consideration of AICAR should be grounded in local regulations and the distinction between exploratory research and validated therapy.

AICAR is classified as a prohibited substance by WADA as a metabolic modulator, specifically as an AMPK activator, under category S4 (Hormone and Metabolic Modulators). It is prohibited both in and out of competition.

Because AICAR occurs endogenously, anti-doping science has had to develop approaches to distinguish natural background levels from exogenous administration, which has made it a frequently discussed compound in the metabolic-modulator category.

Because AICAR influences purine metabolism, one recurring theoretical concern is its potential relationship to uric acid handling. As with other investigational compounds, nonspecific effects and interindividual variability are possible, and long-term safety across diverse populations is not well characterized.

Attention to product sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation.

AICAR is a nucleoside analog that acts intracellularly after conversion to ZMP. Its pharmacology is shaped by cellular uptake, its relatively short duration of activity in some models, and the fact that it engages a broad, systemic energy-sensing pathway rather than a single narrow target.

This information summarizes conceptual pharmacology and does not constitute medical advice or a usage recommendation.

In catalogs, AICAR usually appears as a lyophilized powder for reconstitution and is sometimes grouped alongside compounds associated with metabolism, endurance, or body composition themes.

Structural listings in this catalog are organizational and should not be read as endorsements of specific combinations, regimens, or use cases.

Research on AICAR has examined AMPK activation, mitochondrial biogenesis, glucose uptake, and endurance-related endpoints, primarily in cell and animal models. Some rodent studies generated significant interest in the idea of an "exercise in a pill" concept, but questions about effect size, delivery, and human translation remain.

Because the evidence base is largely preclinical and the human data are limited, claims about AICAR should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this compound, see:

• AICAR benefits and areas of interest
• AICAR side effects and safety context
• AICAR dosing concepts (educational)
• AICAR research and evidence overview

Future FAQs may cover high-level questions such as why AICAR is described as an "exercise mimetic," how it differs from a true peptide, why it is prohibited in sport as a metabolic modulator, and how researchers think about the gap between rodent endurance findings and human outcomes. Answers will remain educational and non-prescriptive.